Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04892680
Other study ID # 2020.082-1
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date March 4, 2021
Est. completion date August 2, 2021

Study information

Verified date May 2022
Source Omada Health, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to evaluate a digital chronic disease self-management program designed to provide virtual support and guidance for patients with type 2 diabetes.


Description:

Approximately 45% of patients with type 2 diabetes do not achieve adequate glycemic control (A1C < 7%). When diabetes is uncontrolled, complications develop that threaten health and endanger life. This study will make an effort to address this growing health challenge and to reduce the burden of diabetes in this population. More broadly, this study will have important implications and benefits for the growing diabetes population in the U.S. Study results will inform future interventions to reduce diabetes and improve outcomes. A better understanding of the efficacy of a digital chronic disease self-management program will directly benefit the participants of the program but, in the future, has the potential to more broadly benefit this population throughout the nation.


Recruitment information / eligibility

Status Terminated
Enrollment 27
Est. completion date August 2, 2021
Est. primary completion date August 2, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Adults at least 18 years of age and less than 65 years of age - Overweight (BMI = 25 kg/m2, or BMI = 23 kg/m2 if of Asian descent) - Uncontrolled type 2 diabetes (HbA1C =7.5% and =12%) - Diagnosed with type 2 diabetes at least 6 months ago, but not more than 10 years ago - Has a compatible smartphone running either Android Operating System 5.0 or higher, or iPhone 7 or later, running iOS 11 or higher. - Willing to set up an online account - An email address in regular use - Ambulatory (e.g., living at home and not in a skilled nursing facility) - Able to speak, understand, and read English Exclusion Criteria: - A diagnosis of Type 1 diabetes - Currently pregnant or postpartum (within 4 weeks) - Currently using a continuous glucose monitor to manage diabetes - Known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin - Skin lesions, scarring, redness, infection or edema at the continuous glucose monitor application sites (upper arm) that could interfere with sensor placement or the accuracy of interstitial glucose measurements - An active eating disorder such as anorexia or bulimia (not including binge-eating disorder) for which he/she has received treatment in the past 12 months - Alcohol or substance abuse that impairs ability to participate in the program - Unable to engage in physical activity for more than 2 months over the next 6 months (i.e. due to injury or recent or planned surgery) - Any of the following in the past 3 months AND are not medically cleared by your physician to exercise: Transient ischemic attack or stroke; Heart attack (myocardial infarction); Hospitalization for congestive heart failure; Cardiac surgery (such as coronary artery bypass grafting (CABG), coronary artery stenting); Bariatric/gastric bypass surgery - Received a solid Organ Transplant (kidney, liver, etc.) within the past 6 months - Recent (within the last 6 months) or planned cancer treatment (chemotherapy, radiation, bone marrow transplant, cancer-related surgery - not including hormonal chemotherapy, such as tamoxifen). - On dialysis treatment - Taking steroids or prednisone (high doses) or getting cortisone injection - Stage 4-5 Chronic Kidney Disease - Class 3-4 Congestive Heart Failure - Participation in diabetes education in the last 30 days

Study Design


Intervention

Behavioral:
Online Diabetes Self-Management Education and Support (DSMES) Program
Digital delivery of a DSMES program designed to build self-management skills and support diabetes management. Recipients have access to online curriculum, a live CDCES, group-based communication forums, and connected technology to track weight, food intake, physical activity and glucose levels.

Locations

Country Name City State
United States Palo Alto Medical Foundation Research Institute Palo Alto California

Sponsors (3)

Lead Sponsor Collaborator
Omada Health, Inc. Palo Alto Medical Foundation, Sutter Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Health care utilization at 6 and 12 months from baseline Patient electronic health record data will be collected to examine the impact on short-term health care utilization Baseline, 6 months, 12 months
Primary Change in HbA1c at 6 months from baseline Non-fasting venous blood sample Baseline, 6 months
Secondary Change in weight at 6 months from baseline Percentage of body weight loss Baseline, 6 months
Secondary Change in medication adherence at 6 months from baseline The Adherence Estimator, a three-item self-report questionnaire, will be used to assess medication adherence Baseline, 6 months
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A